Grimes & Company Inc. Has $2.37 Million Holdings in Pfizer Inc. $PFE

Grimes & Company Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 97,772 shares of the biopharmaceutical company’s stock after buying an additional 2,089 shares during the period. Grimes & Company Inc.’s holdings in Pfizer were worth $2,370,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the stock. GKV Capital Management Co. Inc. bought a new position in Pfizer during the first quarter worth $27,000. North Capital Inc. acquired a new position in shares of Pfizer during the first quarter valued at about $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer during the 1st quarter worth about $28,000. Horizon Financial Services LLC acquired a new stake in shares of Pfizer in the 1st quarter valued at about $35,000. Finally, WPG Advisers LLC bought a new stake in Pfizer in the 1st quarter valued at about $35,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $26.45 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a 50-day moving average of $24.72 and a 200-day moving average of $24.12. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a market cap of $150.38 billion, a P/E ratio of 14.07, a P/E/G ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PFE. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Finally, Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.